Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0005508,
umls-concept:C0016410,
umls-concept:C0022702,
umls-concept:C0032105,
umls-concept:C0086418,
umls-concept:C0178602,
umls-concept:C0178638,
umls-concept:C0220825,
umls-concept:C0221102,
umls-concept:C0348016,
umls-concept:C0442027,
umls-concept:C0442711,
umls-concept:C0680730,
umls-concept:C1148554,
umls-concept:C1524119
|
pubmed:issue |
12
|
pubmed:dateCreated |
1998-1-22
|
pubmed:abstractText |
Stable isotopic protocols for the study of folate absorption were conducted to determine the following: (1) the equivalence of the [13C5] and [2H2] forms of folic acid, and (2) the merits of short-term plasma kinetics from injected and oral doses vs. urinary excretion of [13C5] and [2H2]folates. Another objective was to evaluate the merits of protocols not involving "saturation" of subjects with nonlabeled folate. Oral administration of [13C5] and [2H2]folic acid ( approximately 500 nmol each) to adult subjects (n = 4) yielded an equivalent 24-h urinary excretion of approximately 2% of each dose (molar ratio of urinary [13C5]/[2H2]folates = 0.96 +/- 0.055; mean +/- SEM). Expression of urinary excretion as a ratio of [13C5]/[2H2]folates yielded less within-group variability than seen for absolute excretion of each form of labeled folate. In the second study, subjects received 226 nmol of [2H2]folic acid intravenously and 1010 nmol of [13C5]folic acid orally. Isotopic enrichment of plasma [2H2]folates rose rapidly and returned to near basal values by approximately 2 h postdose. In contrast, enrichment of plasma [13C5]folates was detected until 4 h after dose, whereas enrichment values were far lower than seen with [2H2]folate. Adjusting for the difference in dose, the molar response of plasma area under the curve for isotopic enrichment was 15- to 20-fold greater for injected folates. In view of this very limited short-term plasma response even with a relatively large oral dose, presumably due to hepatic first-pass uptake, these findings suggest that plasma kinetics would be of limited usefulness in assessing the relative bioavailability of nutritionally relevant oral doses of labeled folate.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0022-3166
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
127
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2321-7
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9405581-Administration, Oral,
pubmed-meshheading:9405581-Adult,
pubmed-meshheading:9405581-Biological Availability,
pubmed-meshheading:9405581-Carbon Isotopes,
pubmed-meshheading:9405581-Deuterium,
pubmed-meshheading:9405581-Female,
pubmed-meshheading:9405581-Folic Acid,
pubmed-meshheading:9405581-Humans,
pubmed-meshheading:9405581-Injections, Intravenous,
pubmed-meshheading:9405581-Isotope Labeling,
pubmed-meshheading:9405581-Male
|
pubmed:year |
1997
|
pubmed:articleTitle |
A dual-label stable-isotopic protocol is suitable for determination of folate bioavailability in humans: evaluation of urinary excretion and plasma folate kinetics of intravenous and oral doses of [13C5] and [2H2]folic acid.
|
pubmed:affiliation |
Food Science and Human Nutrition Department, University of Florida, Gainesville, FL 32611, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, Non-P.H.S.,
Controlled Clinical Trial
|